Related Experiment Videos
Hypertension treatment and prevention of new atherosclerotic plaque formation
1Hannover Medical School, Germany.
Insights
Hypertension causes arterial wall changes that promote atherosclerosis. Calcium antagonists may prevent this by reducing blood pressure and inhibiting cellular processes involved in early atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Vascular Medicine
- Hypertension Research
Background:
- Hypertension induces endothelial dysfunction and smooth muscle cell hypertrophy.
- Endothelial injury in hypertension promotes platelet aggregation and growth factor release.
- These changes contribute to arterial wall thickening and increased vascular resistance.
Purpose of the Study:
- To investigate the role of hypertension in arterial wall changes.
- To explore the potential of calcium antagonists in mitigating hypertensive vascular damage and early atherosclerosis.
Main Methods:
- Morphological analysis of arterial vascular wall in hypertension.
- Assessment of endothelial permeability and cellular proliferation.
- Evaluation of platelet aggregation and growth factor involvement.
- Examination of calcium ions' role as intracellular signals.
Main Results:
- Hypertension leads to endothelial dysfunction, smooth muscle cell proliferation, and lipid accumulation.
- These processes are common to both hypertension and early atherosclerosis.
- Calcium ions are implicated as key mediators in these vascular changes.
Conclusions:
- Calcium antagonists may offer dual benefits: reducing blood pressure and inhibiting atherosclerosis initiation.
- Evidence suggests a beneficial effect of calcium antagonists on early atherosclerotic processes.
- Targeting calcium signaling could be a therapeutic strategy for hypertensive cardiovascular protection.
Abstract:
The effect of hypertension on the arterial vascular wall is characterised primarily by morphological changes to the endothelium and hypertrophy of smooth muscle cells within the arterial media. Endothelial dysfunction is manifest through increased permeability to high molecular weight compounds as well as mitogenic and vasoactive substances. At the same time, denudation of the vascular endothelium promotes platelet aggregation and subsequent release of platelet-derived growth factor (PDGF). In conjunction with endothelium- and monocyte-derived growth factors, this mitogen stimulates subintimal smooth muscle cell proliferation and migration and arterial wall thickening, resulting in a haemodynamically important increase in vascular resistance, particularly at the precapillary level. In addition, focal endothelial dysfunction allows entry of lipids into the vascular wall, thereby promoting formation of a lipid-rich fatty streak, the primary 'early' atherosclerotic lesion. Most of these changes, including endothelial injury, subintimal lipid-binding, cellular proliferation and migration, platelet aggregation and PDGF release are common to both hypertensive and early atherosclerotic processes and involve the participation of calcium ions as 'second messengers'. Thus, antihypertensive treatment with calcium antagonists may not only lead to a protective decrease in wall shear stress through a reduction in blood pressure, but may also inhibit those cellular processes within the vascular wall that are responsible for initiating atherosclerosis. Indeed, experimental as well as human studies have demonstrated a beneficial suppressant effect of calcium antagonists on the early stages of atherosclerosis.